Kelch-like protein 11 autoantibodies: A novel biomarker of testicular cancer associated neurological autoimmunity

Expires: July 22, 2024

Overview

This “Specialty Testing” webinar will discuss the collaborative effort that led to the discovery of Kelch-like protein 11 (KLHL11) IgG as a specific biomarker of neurological autoimmunity-associated testicular germ cell tumors. Recognizing these clinical and radiological features of KLHL11 autoimmunity can avoid delays in diagnosis. Insights into the etiopathogenic mechanism of this cytotoxic-T cell-mediated syndrome may help with formulation of therapeutic strategies. Furthermore, understanding the diagnostic potential and limitations of KLHL11 IgG detection assays may aid the managing clinicians in optimal test interpretation.

Presentation

Presenter

Divyanshu Dubey, M.B.B.S., portrait square

Divyanshu Dubey, M.B.B.S.

Assistant Professor of Laboratory Medicine and Pathology and Neurology
Division of Clinical Biochemistry
Mayo Clinic, Rochester, Minnesota

Learning objectives

Upon completion of this activity, participants should be able to:

  • Recognize novel paraneoplastic syndrome associated with testicular germ cell tumors 
  • Review techniques utilized for autoantigen discovery 
  • Review immunopathological data providing insight into KLHL11 encephalitis pathogenesis

Intended audience

This webinar is designed for any provider who sees patients with neurologic diseases (e.g., neurologists, psychiatrists, and primary care physicians, including internists and family care practitioners) as well as pathologists, laboratory directors, and laboratory send-out coordinators.

Faculty disclosure

Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.

Learn more about our testing

Questions?

Contact us: mcleducation@mayo.edu

MCL Education (@mmledu)

MCL Education

This post was developed by our Education and Technical Publications Team.